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Hepatitis viruses are some of the many occupational infectious blood-
borne pathogens for which healthcare workers (HCWs) are at risk. 
The hazard is particularly severe in some developing countries, where 
as many as 47% of hepatitis B virus (HBV) and 45% of hepatitis C 
virus (HCV) infections are the result of percutaneous occupational 
exposures.1 
HBV is endemic in South Africa. The South African black population 
has the highest incidence of infection,2 with prevalences of antibody to 
the hepatitis B surface antigen (anti-HBs) of 42.9%, 3.4%, and 1.2% in 
black, Asian, and Caucasian blood donors, respectively.2,3 The HBV 
carrier rate (as evidenced by the persistent presence of hepatitis B 
surface antigen (HBsAg) in the individual’s serum) in South African 
blacks is approximately 9%, with the black population in rural areas 
having significantly higher rates (10%) than those in urban areas 
(1%).4 In the Caucasian and Asian populations carrier rates are low, 
being 0.23% and 0.18% in Caucasian South African men and women, 
respectively.5 In contrast, the seroprevalence of HCV infection is low in 
all South African populations,4,6 the anti-HCV prevalence being 1.2%, 
0.8%, and 0.6% in blacks, Asians, and Caucasians, respectively.3 It has 
been estimated that an HCW’s overall risk of contracting hepatitis is 
four times greater than that of the general adult population.7 The risk to 
HCWs in South Africa has not been determined, although it probably 
is at least as high as that in Brazil.8,9  
Approximately 5.7 million South Africans are currently living with 
HIV, with 8.8% of the adult population aged between 15 and 49 years 
being infected.10
Of HIV-infected individuals, 66%10,11 have evidence of either 
past or present infection with HBV. Because HBV vaccine has been 
included in the Expanded Programme on Immunization (EPI) in 
South Africa only since 1995, these individuals would not have been 
immunised at birth and would therefore have been susceptible to 
HBV infection.6 The prevalence of HIV/HBV co-infection in the 
South African population ranges between 6% and 17%.11,12 In the 
USA between 50% and 90% of HIV-infected people have serological 
markers of past HBV infection and 5-10% are chronic carriers of 
the virus.13 Anti-HCV antibody testing in 1 649 CAESAR study 
participants demonstrated an HIV/HCV co-infection prevalence of 
1.9% in South Africa.14
Deaths among HIV-infected people with chronic HBV and HCV 
infections, now seen as a result of end-stage liver disease, have 
increased worldwide.15 Studies by Lukhwareni et al.10 strongly support 
the policy that all HIV-positive patients initiating highly active 
antiretroviral therapy (HAART) in South Africa be screened for HBV, 
and the Centers for Disease Control (CDC) in the USA recommend 
that all HIV-infected HCWs be vaccinated against HBV.16
Studies on the impact of HIV/AIDS on the health sector in four 
provinces in South Africa in 2002 and in two public hospitals in 
Johannesburg in 2005 estimated the HIV seroprevalence among 
HCWs to be 15.7%17 and 11.5%18 respectively. In South Africa, 
vaccination against HBV is available at no cost to all HCWs at 
risk,19 yet HCWs remain susceptible. At an academic hospital in 
Johannesburg in 1996, among 402 HCWs, of whom 80.6% were 
blacks and 19.4% whites, 30.6% had HBV antibodies and 1.8% tested 
positive for HCV antibodies.20 In Denmark, where the prevalence 
of blood-borne viral infections is low, the prevalence of HIV, HCV 
and HBV was 0%, 0.14% and 1.6% respectively among HCWs in an 
academic hospital.21
Our purpose was to re-examine the nurses working predominantly 
in the medical wards of the same academic hospital in Johannesburg20 
to re-assess the prevalence of occupational viral infections. The study 
participants were predominantly black (83.6%) and female (95.3%). 
Methods 
The study was conducted in a 1 000-bed tertiary academic hospital. 
As part of a larger cross-sectional study, nurses were screened for 
ORIGINAL ARTICLES
Nurses at risk for occupationally acquired blood-borne virus 
infection at a South African academic hospital   
 T Mosendane, M C Kew, R Osih, A Mahomed
Aim. We aimed to ascertain if there had been any improvement in the 
number of nurses being immunised against hepatitis B virus (HBV) 
infection in a large academic hospital in which, 10 years previously, 
only 30.6% of the nurses were immune to infection with the virus, 
and to ascertain the incidence of infection with hepatitis C virus 
(HCV) and human immunodeficiency virus (HIV) in these nurses. 
Methods. We studied 170 predominantly black nurses. 
Their blood was tested for the presence of active or past HBV 
infection using appropriate immunoassays, HCV infection by 
chromatographic immunoassays confirmed by polymerase chain 
reaction assays, and HIV using a rapid test confirmed by enzyme-
linked immunosorbent assays. 
Results. Serum of 89 (52.4%) nurses was positive for hepatitis 
B surface antibody (anti-HBs). Of these nurses 18 said that they 
had not received the vaccine; the serum of 9 of these was positive 
for anti-hepatitis B core antibody (anti-HBc) as well as anti-HBs, 
indicating natural infection with the virus. Of the nurses positive 
for anti-HBs, 89 were tested for anti-HBc; 28.2% tested positive for 
anti-HBc. Three nurses gave dates of immunisation that fell outside 
of their nursing careers; 3 (1.8%) were actively infected with the 
virus; 2 (1.8%) were infected with HCV; 10 nurses (5.9%) were 
positive for HIV.
Conclusion. Nurses at this academic hospital remain at high risk 
of work-related HBV infection.
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serological markers of HBV, HCV and HIV antibodies from March 
to November 2008. Nurses, including student nurses, registered 
with the South African Nursing Council, who were willing to give 
consent to be tested for HBV, HCV and HIV and to receive test 
results were eligible to participate. Nurses were recruited from the 
general medical wards, oncology ward, medical intensive care unit 
(ICU), neurosurgical ICU, phlebotomy room, neurology ward and 
the outpatient departments. Their demographic characteristics are 
shown in Table 1. 
The study was initially discussed with the nursing managers 
in charge of the various wards and ICUs, who then assisted with 
recruitment. Some nurses who had heard of the study from colleagues 
requested to be enrolled. The overall response rate of nurses who 
were approached and those who referred themselves to the study 
was 96%. All participants gave informed consent. This study was 
approved by the Human Ethics Committee of the University of the 
Witwatersrand and the hospital management.  
Personal interviews, pre-test counselling, examinations and 
post-test counselling were conducted confidentially. Nurses were 
questioned regarding previous HBV vaccination, including booster 
doses, a history of needlestick injuries in the last 2 years, knowledge 
of their HIV status, when they had last had an HIV test, and of any 
general medical illness. 
A venous blood sample was taken from each nurse to screen for 
HBV. 
Coded blood samples were sent to the National Institute of 
Virology (NIV) for analysis. HBsAg was tested using ADVIA 
Centaur® HBsAg immunoassay kit (Siemens Healthcare Diagnostics), 
anti-HBs levels were determined using ADVIA Centaur® Anti-HBs 
immunoassay kit (Siemens Healthcare Diagnostics), hepatitis B core 
(HBc) immunoglobulin M (IgM) was tested using ADVIA Centaur® 
HBc IgM immunoassay kit (Siemens Healthcare Diagnostics) and 
HBc total antibody (Ab) was tested using ADVIA Centaur® HBc 
Total immunoassay kit (Siemens Healthcare Diagnostics). Hepatitis 
B e antigen (HBeAg) was detected using ADVIA Centaur® HBeAg 
immunoassay kit (Siemens Healthcare Diagnostics), and lastly HBe 
Ab used the ADVIA Centaur® Anti-HBe immunoassay kit (Siemens 
Healthcare Diagnostics).
Nurses who had low levels of immunity against HBV (anti-HBs 
titres <100 mIU/l) and who had not had boosters were referred for 
vaccination within the hospital. Nurses who were identified as having 
acute or chronic HBV infection were referred to the hospital liver 
clinic for further management and follow up. Genotyping for HBV was 
not available at that time. Whole blood specimens were also taken to 
screen for HCV antibodies using rapid chromatographic immunoassay 
kits (ACON Laboratories) for the qualitative detection of antibody to 
hepatitis C virus (anti-HCV). Those found to have positive screening 
tests for HCV were also referred to the liver clinic. At the liver clinic 
all positive HCV screening tests were confirmed by the NIV using 
polymerase chain reaction (PCR). All positive confirmatory PCRs then 
underwent genotyping as per the Department of Health’s standard of 
care guidelines. HIV screening was performed using rapid testing 
kits (Humor Diagnostica). The manufacturer’s instructions for the 
HIV and HCV tests were followed strictly and positive results were 
determined as per kit recommendations. All positive rapid HIV tests 
were confirmed by HIV enzyme-linked immunosorbant assay (Abbot 
Diagnostics). HIV and HCV results were immediately made available 
to the participants. Hepatitis results were returned to the nurses once 
laboratory made results available. Appropriate post-test counselling 
and advice were given to all participants. All results were returned 
to the participants only and there was no disclosure to participant’s 
supervisors or the employer.
Results 
 A total of 170 nurses (162 females and 8 males) participated. Their 
mean age was 41.0 years (range 19 - 61 years). The prevalence of 
HBsAg was 1.8% (3/170) (all were black nurses). HBV e antigen 
(HBeAg) was detected in one of these three nurses and was associated 
with a positive screen for IgM antibodies to HBV core antigen (IgM-
anti-HBc), indicating a recent infection. The other two were positive 
for antibody to HBV e antigen (anti-HBe). Immunity against HBV, 
defined as an anti-HBs titre >10 IU/l, was found in 52.4% (89/170) 
of nurses. To ascertain in how many more of the HCWs HBV 
infection may have been acquired naturally, anti-HBc was tested in 
89 nurses testing positive for anti-HBs, 18 of whom reported that 
they had never been immunised against HBV (Fig. 1). The serum 
of 9 was positive for anti-HBs and anti-HBc, indicating that they 
had been infected naturally. A further 6 were positive for anti-HBs 
alone. However, a possible explanation for this finding could be that 
the nurses were unable to recall their vaccination history because of 
a long duration of service. There were no data available regarding 
anti-HBc for three nurses as a result of insufficient serum (Fig. 1). To 
ascertain in how many more of the HCWs HBV infection may have 
been acquired naturally, anti-HBc was tested in 71 nurses testing 
positive for anti-HBs (a marker of infection acquired naturally and 
not by vaccination); 20 (28.2%) tested positive for anti-HBc (Table 2); 
22 (25.3%) gave a history of being vaccinated ranging from 16 years 
before to the present, but had no serological evidence of immunity 
(anti-HBs <10 mIU/ml). Three nurses gave dates of immunisation 
that fell outside of their nursing careers. None who tested positive 
for anti-HBs gave a history of needlestick injury. The prevalence of 
antibodies to HCV in this group of HCWs was 1.2% (2/170). 
Although 90.5% (154/170) of nurses gave a history of having had 
an HIV test in the past, only 46.5% (79/170) had been tested within 
the last 2 years. An overall HIV seroprevalence of 5.9% (10/170) was 
found, with 4 being newly diagnosed. Only 1 nurse, with an absolute 
CD4 count of 77 x 106/l, was taking antiretroviral therapy. 
Of the 10 nurses infected with HIV, 5 reported that they had not 
been vaccinated (the serum of 1 was positive for anti-HBs). Of 5 
who were recently vaccinated all but 1 were non-responders or low-
responders, with anti-HBs titres of ≤ 55 mIU/ml.
Dual infections of HIV and HBV, HIV and HCV, and HBV and 
HCV were not found.
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Table 1. Demographic features of nurses
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Discussion
A study 10 years ago showed that only 30.6% of nurses in an academic 
hospital in Johannesburg were positive for anti-HBs, indicating 
resistance to HBV infection.19 At that time recommendations 
were made for a cost-effective approach to the prevention and 
management of viral hepatitis in HCWs.20 Our follow-up study at 
the same hospital  a decade later indicates that, at most, only 52.4% 
of the nurses are now protected against HBV infection. However, as 
many as 28.6% of these nurses were anti-HBc-positive indicating 
that they had acquired the infection naturally. A further 1.8% of 
the nurses were currently infected with the virus. Clearly, more 
intensive education regarding the importance of HB vaccination 
and more thorough monitoring and immunisation of the nursing 
staff is required.  
Reasons given by the nurses for HB vaccinations not being 
done included: not being aware of the danger of hepatitis as an 
occupational exposure, not being aware of the availability of a vaccine 
that would prevent hepatitis infection, not having enough time, and 
being told that the stock of vaccine vials had run out.
The nurse found to be IgM-antiHBc positive was asymptomatic, 
and more than 6 months after the initial screening test she remains 
positive for HBsAg and HBeAg. She was referred to the hospital liver 
unit. Of the nurses who screened positive for anti-HBs, none recalled 
having received a needlestick injury.
Evidence of acquired 
immunity was highest among 
nurses aged between 40 and 
49 years (Table 3). In recent 
years strict pre-employment 
screening and follow-up 
programmes have no longer 
been conducted, which may 
have contributed to the 
higher rate of nurses being 
vaccinated in earlier years. 
Of the 22 nurses who 
could provide a history of 
the year in which they were 
vaccinated, 10 would have 
been above the age of 30 
when they were vaccinated. 
Risk factors for a reduced 
response to vaccination 
include age >30 years, obesity, 
and immunodeficiency.21 
Response rates to HB 
vaccination in HIV-infected 
individuals are as low as 
18 - 62%, and a CD4 count 
<200 has been shown to be 
an independent predictor of 
reduced response.20 These 
factors could explain why 
4 of the 5 nurses who were 
HIV positive and gave a 
history of recent vaccination 
were non-responders or 
low-responders, with anti-
HBs titres of ≤55 mIU/
ml. It is suggested that HB 
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Table 2. Number of nurses with anti-HBs titre >10 IU/l catego-
rised into anti-HBs and anti-HBc and segregated by gender 
and race
Demographics
Number (%) of 
participants with anti-
HBs positivity 




Total 89 (52.4) 20 (22.5)
Males 3 (3.4) 0
Females 86 (96.6) 20
Race
Black 72 (80.9) 17 (85)
Coloured 6 (6.7) 1 (5)
White 9 (10.1) 2 (10)
Indian 1 (1.1) 0
Chinese 1 (1.1) 0
Anti-HBs – antibody to hepatitis B surface antigen, anti-HBc – antibody to hepatitis B core 
antigen
Fig. 1. Analysis of results once total number of nurses who were hepatitis B surface (antigen) (HBs)-positive are segregated 






No Hx of  
vaccination
18
60 HBs only 11 HBs + HBc





156 March 2012, Vol. 102, No. 3  SAMJ
vaccination should be initiated early in the course of HIV infection, 
before patients become extremely immunosuppressed.22 
A high HBV infection rate and low vaccine coverage among 
HCWs, including nurses, has also been documented in Kenya23 and 
Albania.24
The prevalence of HCV infection in this study is in keeping with 
that of the general population. One nurse was aware of her HCV 
status because she had acquired the infection from a patient as a 
result of a needlestick injury. The second nurse was unaware of her 
HCV status.
The HIV seroprevalence of HIV of 5.9% in this study was lower 
than that of the general population. HIV testing among the nurses is 
low and infrequent as fear of stigmatisation remains an issue among 
nurses, preventing them from testing and knowing their HIV status. 
Previous studies that assessed the seroprevalence among HCWs 
did not return the results to the participants and incentives were 
given to encourage participation. Returning HIV test results to the 
participants could thus have contributed to a biased sample. Nurses 
who may have wanted to participate, but were unsure of their HIV 
status and were not prepared to deal with a new diagnosis of a chronic 
illness may not have tested. In addition, nurses who may have known 
their status, but were not comfortable to disclose this information 
may have opted not to enroll in the study.
Vardas et al.20 presented an extensive series of recommendations 
for the prevention of hepatitis A, B and C in South African HCWs. 
However, this study, essentially 10 years later, shows that in the same 
institution HCWs remain at high risk. HCW, healthcare facility 
managers, and the Department of Health, must be far more active 
in comprehensive prescreening medical assessments and increasing 
educational awareness among HCWs, and give serious consideration 
to a hepatitis B vaccine catch-up programme. 
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No. of participants 
(%)  with 
anti-HBc positivity
20 - 29 10 (11.2) 0
30 - 39 21 (23.6) 3 (15)
40 - 49 37 (41.6) 11 (55)
50 - 59 16 (18) 2 (10)
>60 5 (5.6) 1 (5)
Anti-HBs = antibody to hepatitis B surface antigen; anti-HBc = antibody to hepatitis B core 
antigen..
